The global Opioid Induced Constipation (OIC) Drug market size is expected to reach US$ 3490.4 million by 2029, growing at a CAGR of 4.6% from 2023 to 2029.

Opioid Induced Constipation (OIC) Drug - Market

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

The market is mainly driven by the significant applications of Opioid Induced Constipation (OIC) Drug in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Opioid Induced Constipation (OIC) Drug market. Lubiprostone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Methyl Naltrexone Bromide segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by manufacturers, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioid Induced Constipation (OIC) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Opioid Induced Constipation (OIC) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Opioid Induced Constipation (OIC) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioid Induced Constipation (OIC) Drug sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Opioid Induced Constipation (OIC) Drug covered in this report include Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma and S.L.A. Pharma, etc.

The global Opioid Induced Constipation (OIC) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

Ironwood Pharmaceuticals

Daiichi Sankyo Co

Pfizer

Progenics Pharmaceuticals

Shionogi &

Allergan

Nektar Therapeutics

Purdue Pharma

S.L.A. Pharma

Mundipharma International Limited

Ono Pharmaceutical

Takeda Pharmaceutical Company Limited

Theravance Biopharma

Bausch Health

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

C.B. Fleet Company

Sucampo Pharmaceuticals

Scope of Opioid Induced Constipation (OIC) Drug - Market Report

Report Metric	Details
Report Name	Opioid Induced Constipation (OIC) Drug - Market
Forecasted market size in 2029	US$ 3490.4 million
CAGR	4.6%
Forecasted years	2023 - 2029
Global Opioid Induced Constipation (OIC) Drug market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioid Induced Constipation (OIC) Drug market, Segment by Type:	Lubiprostone Methyl Naltrexone Bromide Naldemedine Alvimopan Other Global Opioid Induced Constipation (OIC) Drug market, by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Distribution Channel, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.

FAQ for this report

What is the Opioid Induced Constipation (OIC) Drug - Market size in 2029?

Ans: The Opioid Induced Constipation (OIC) Drug - Market size in 2029 will be US$ 3490.4 million.

What are the Type segmentation covered in the Opioid Induced Constipation (OIC) Drug - Market report?

Ans: The Types covered in the Opioid Induced Constipation (OIC) Drug - Market report are Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, Global Opioid Induced Constipation (OIC) Drug market, by Distribution Channel, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

1 Opioid Induced Constipation (OIC) Drug Market Overview

1.1 Opioid Induced Constipation (OIC) Drug Product Overview

1.2 Opioid Induced Constipation (OIC) Drug Market Segment by Type

1.2.1 Lubiprostone

1.2.2 Methyl Naltrexone Bromide

1.2.3 Naldemedine

1.2.4 Alvimopan

1.2.5 Other

1.3 Global Opioid Induced Constipation (OIC) Drug Market Size by Type

1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Type (2018-2029)

1.3.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Type (2018-2023)

1.3.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Type (2024-2029)

1.4 Key Regions Market Size Segment by Type

1.4.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)

1.4.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)

1.4.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)

1.4.4 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)

1.4.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)

2 Global Opioid Induced Constipation (OIC) Drug Market Competition by Company

2.1 Global Top Players by Opioid Induced Constipation (OIC) Drug Sales (2018-2023)

2.2 Global Top Players by Opioid Induced Constipation (OIC) Drug Revenue (2018-2023)

2.3 Global Top Players by Opioid Induced Constipation (OIC) Drug Price (2018-2023)

2.4 Global Top Manufacturers Opioid Induced Constipation (OIC) Drug Manufacturing Base Distribution, Sales Area, Product Type

2.5 Opioid Induced Constipation (OIC) Drug Market Competitive Situation and Trends

2.5.1 Opioid Induced Constipation (OIC) Drug Market Concentration Rate (2018-2023)

2.5.2 Global 5 and 10 Largest Manufacturers by Opioid Induced Constipation (OIC) Drug Sales and Revenue in 2022

2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation (OIC) Drug as of 2022)

2.7 Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market

2.8 Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Offered

2.9 Mergers & Acquisitions, Expansion

3 Opioid Induced Constipation (OIC) Drug Status and Outlook by Region

3.1 Global Opioid Induced Constipation (OIC) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029

3.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size by Region

3.2.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2018-2023)

3.2.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2018-2023)

3.2.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)

3.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Region

3.3.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2024-2029)

3.3.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2024-2029)

3.3.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)

4 Global Opioid Induced Constipation (OIC) Drug by Distribution Channel

4.1 Opioid Induced Constipation (OIC) Drug Market Segment by Distribution Channel

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Opioid Induced Constipation (OIC) Drug Market Size by Distribution Channel

4.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Distribution Channel (2018-2029)

4.2.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Distribution Channel (2018-2023)

4.2.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Distribution Channel (2024-2029)

4.3 Key Regions Market Size Segment by Distribution Channel

4.3.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)

4.3.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)

4.3.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)

4.3.4 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)

4.3.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)

5 North America Opioid Induced Constipation (OIC) Drug by Country

5.1 North America Opioid Induced Constipation (OIC) Drug Historic Market Size by Country

5.1.1 North America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029

5.1.2 North America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)

5.1.3 North America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)

5.2 North America Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country

5.2.1 North America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)

5.2.2 North America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)

6 Europe Opioid Induced Constipation (OIC) Drug by Country

6.1 Europe Opioid Induced Constipation (OIC) Drug Historic Market Size by Country

6.1.1 Europe Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029

6.1.2 Europe Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)

6.1.3 Europe Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)

6.2 Europe Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country

6.2.1 Europe Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)

6.2.2 Europe Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)

7 Asia-Pacific Opioid Induced Constipation (OIC) Drug by Region

7.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Historic Market Size by Region

7.1.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029

7.1.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2018-2023)

7.1.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2018-2023)

7.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Region

7.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2024-2029)

7.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2024-2029)

8 Latin America Opioid Induced Constipation (OIC) Drug by Country

8.1 Latin America Opioid Induced Constipation (OIC) Drug Historic Market Size by Country

8.1.1 Latin America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029

8.1.2 Latin America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)

8.1.3 Latin America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)

8.2 Latin America Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country

8.2.1 Latin America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)

8.2.2 Latin America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)

9 Middle East and Africa Opioid Induced Constipation (OIC) Drug by Country

9.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Historic Market Size by Country

9.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029

9.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)

9.1.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)

9.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country

9.2.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)

9.2.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)

10 Company Profiles

10.1 Ironwood Pharmaceuticals

10.1.1 Ironwood Pharmaceuticals Company Information

10.1.2 Ironwood Pharmaceuticals Introduction and Business Overview

10.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered

10.1.5 Ironwood Pharmaceuticals Recent Development

10.2 Daiichi Sankyo Co

10.2.1 Daiichi Sankyo Co Company Information

10.2.2 Daiichi Sankyo Co Introduction and Business Overview

10.2.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Products Offered

10.2.5 Daiichi Sankyo Co Recent Development

10.3 Pfizer

10.3.1 Pfizer Company Information

10.3.2 Pfizer Introduction and Business Overview

10.3.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Products Offered

10.3.5 Pfizer Recent Development

10.4 Progenics Pharmaceuticals

10.4.1 Progenics Pharmaceuticals Company Information

10.4.2 Progenics Pharmaceuticals Introduction and Business Overview

10.4.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered

10.4.5 Progenics Pharmaceuticals Recent Development

10.5 Shionogi &

10.5.1 Shionogi & Company Information

10.5.2 Shionogi & Introduction and Business Overview

10.5.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Products Offered

10.5.5 Shionogi & Recent Development

10.6 Allergan

10.6.1 Allergan Company Information

10.6.2 Allergan Introduction and Business Overview

10.6.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.6.4 Allergan Opioid Induced Constipation (OIC) Drug Products Offered

10.6.5 Allergan Recent Development

10.7 Nektar Therapeutics

10.7.1 Nektar Therapeutics Company Information

10.7.2 Nektar Therapeutics Introduction and Business Overview

10.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.7.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Products Offered

10.7.5 Nektar Therapeutics Recent Development

10.8 Purdue Pharma

10.8.1 Purdue Pharma Company Information

10.8.2 Purdue Pharma Introduction and Business Overview

10.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Products Offered

10.8.5 Purdue Pharma Recent Development

10.9 S.L.A. Pharma

10.9.1 S.L.A. Pharma Company Information

10.9.2 S.L.A. Pharma Introduction and Business Overview

10.9.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Products Offered

10.9.5 S.L.A. Pharma Recent Development

10.10 Mundipharma International Limited

10.10.1 Mundipharma International Limited Company Information

10.10.2 Mundipharma International Limited Introduction and Business Overview

10.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Products Offered

10.10.5 Mundipharma International Limited Recent Development

10.11 Ono Pharmaceutical

10.11.1 Ono Pharmaceutical Company Information

10.11.2 Ono Pharmaceutical Introduction and Business Overview

10.11.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.11.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Products Offered

10.11.5 Ono Pharmaceutical Recent Development

10.12 Takeda Pharmaceutical Company Limited

10.12.1 Takeda Pharmaceutical Company Limited Company Information

10.12.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview

10.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Products Offered

10.12.5 Takeda Pharmaceutical Company Limited Recent Development

10.13 Theravance Biopharma

10.13.1 Theravance Biopharma Company Information

10.13.2 Theravance Biopharma Introduction and Business Overview

10.13.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.13.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Products Offered

10.13.5 Theravance Biopharma Recent Development

10.14 Bausch Health

10.14.1 Bausch Health Company Information

10.14.2 Bausch Health Introduction and Business Overview

10.14.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.14.4 Bausch Health Opioid Induced Constipation (OIC) Drug Products Offered

10.14.5 Bausch Health Recent Development

10.15 Cosmo Pharmaceuticals SA

10.15.1 Cosmo Pharmaceuticals SA Company Information

10.15.2 Cosmo Pharmaceuticals SA Introduction and Business Overview

10.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Products Offered

10.15.5 Cosmo Pharmaceuticals SA Recent Development

10.16 Daewoong Pharmaceutical

10.16.1 Daewoong Pharmaceutical Company Information

10.16.2 Daewoong Pharmaceutical Introduction and Business Overview

10.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Products Offered

10.16.5 Daewoong Pharmaceutical Recent Development

10.17 C.B. Fleet Company

10.17.1 C.B. Fleet Company Company Information

10.17.2 C.B. Fleet Company Introduction and Business Overview

10.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Products Offered

10.17.5 C.B. Fleet Company Recent Development

10.18 Sucampo Pharmaceuticals

10.18.1 Sucampo Pharmaceuticals Company Information

10.18.2 Sucampo Pharmaceuticals Introduction and Business Overview

10.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)

10.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered

10.18.5 Sucampo Pharmaceuticals Recent Development

11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis

11.1 Opioid Induced Constipation (OIC) Drug Key Raw Materials

11.1.1 Key Raw Materials

11.1.2 Key Raw Materials Price

11.1.3 Raw Materials Key Suppliers

11.2 Manufacturing Cost Structure

11.2.1 Raw Materials

11.2.2 Labor Cost

11.2.3 Manufacturing Expenses

11.3 Opioid Induced Constipation (OIC) Drug Industrial Chain Analysis

11.4 Opioid Induced Constipation (OIC) Drug Market Dynamics

11.4.1 Opioid Induced Constipation (OIC) Drug Industry Trends

11.4.2 Opioid Induced Constipation (OIC) Drug Market Drivers

11.4.3 Opioid Induced Constipation (OIC) Drug Market Challenges

11.4.4 Opioid Induced Constipation (OIC) Drug Market Restraints

12 Market Strategy Analysis, Distributors

12.1 Sales Channel

12.2 Opioid Induced Constipation (OIC) Drug Distributors

12.3 Opioid Induced Constipation (OIC) Drug Downstream Customers

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

14.3 Disclaimer

FEATURED COMPANIES

Ironwood Pharmaceuticals

Daiichi Sankyo Co

Pfizer Inc

Progenics Pharmaceuticals

Mundipharma International Limited

Ono Pharmaceutical

Takeda Pharmaceutical Company Limited

Theravance Biopharma

Bausch Health

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

C. B. Fleet Company

Sucampo Pharmaceuticals

List of Tables

Table 1. Major Company of Lubiprostone

Table 2. Major Company of Methyl Naltrexone Bromide

Table 3. Major Company of Naldemedine

Table 4. Major Company of Alvimopan

Table 5. Major Company of Other

Table 6. Global Opioid Induced Constipation (OIC) Drug Sales by Type 2018 VS 2022 VS 2029 (US$ Million)

Table 7. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (K Units)

Table 8. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type (2018-2023)

Table 9. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US& Million)

Table 10. Global Opioid Induced Constipation (OIC) Drug Market Share in Value by Type (2018-2023)

Table 11. Global Opioid Induced Constipation (OIC) Drug Price by Type (2018-2023) & (USD/Unit)

Table 12. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2024-2029) & (K Units)

Table 13. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type (2024-2029)

Table 14. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2024-2029) & (US$ Million)

Table 15. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type (2024-2029)

Table 16. Global Opioid Induced Constipation (OIC) Drug Price by Type (2024-2029) & (USD/Unit)

Table 17. North America Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (K Units)

Table 18. North America Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US$ Million)

Table 19. Europe Opioid Induced Constipation (OIC) Drug Sales (K Units) by Type (2018-2023)

Table 20. Europe Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US$ Million)

Table 21. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales (K Units) by Type (2018-2023)

Table 22. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US$ Million)

Table 23. Latin America Opioid Induced Constipation (OIC) Drug Sales (K Units) by Type (2018-2023)

Table 24. Latin America Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US$ Million)

Table 25. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales (K Units) by Type (2018-2023)

Table 26. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2023) & (US$ Million)

Table 27. Global Opioid Induced Constipation (OIC) Drug Sales by Company (2018-2023) & (K Units)

Table 28. Global Opioid Induced Constipation (OIC) Drug Sales Share by Company (2018-2023)

Table 29. Global Opioid Induced Constipation (OIC) Drug Revenue by Company (2018-2023) & (US$ Million)

Table 30. Global Opioid Induced Constipation (OIC) Drug Revenue Share by Company (2018-2023)

Table 31. Global Market Opioid Induced Constipation (OIC) Drug Price by Company (2018-2023) & (USD/Unit)

Table 32. Global Opioid Induced Constipation (OIC) Drug Top Manufacturers Manufacturing Base Distribution and Sales Area

Table 33. Global Opioid Induced Constipation (OIC) Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 34. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation (OIC) Drug as of 2022)

Table 35. Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market

Table 36. Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Type

Table 37. Mergers & Acquisitions, Expansion Plans

Table 38. Global Opioid Induced Constipation (OIC) Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029

Table 39. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2018-2023) & (K Units)

Table 40. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2018-2023)

Table 41. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2018-2023) & (US$ Million)

Table 42. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2018-2023)

Table 43. Global Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 44. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2024-2029) & (K Units)

Table 45. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2024-2029)

Table 46. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2024-2029) & (US$ Million)

Table 47. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2024-2029)

Table 48. Global Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)

Table 49. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel: 2018 VS 2022 VS 2029 (US$ Million)

Table 50. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (K Units)

Table 51. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel (2018-2023)

Table 52. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 53. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel (2018-2023)

Table 54. Global Opioid Induced Constipation (OIC) Drug Price by Distribution Channel (2018-2023) & (USD/Unit)

Table 55. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2024-2029) & (K Units)

Table 56. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel (2024-2029)

Table 57. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2024-2029) & (US$ Million)

Table 58. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel (2024-2029)

Table 59. Global Opioid Induced Constipation (OIC) Drug Price by Distribution Channel (2024-2029) & (USD/Unit)

Table 60. North America Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) (K Units)

Table 61. North America Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 62. Europe Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) (K Units)

Table 63. Europe Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 64. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) (K Units)

Table 65. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 66. Latin America Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) (K Units)

Table 67. Latin America Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 68. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) (K Units)

Table 69. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2023) & (US$ Million)

Table 70. North America Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (K Units)

Table 71. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2018-2023)

Table 72. North America Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (US$ Million)

Table 73. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2018-2023)

Table 74. North America Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (K Units)

Table 75. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2024-2029)

Table 76. North America Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (US$ Million)

Table 77. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2024-2029)

Table 78. Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (K Units)

Table 79. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2018-2023)

Table 80. Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (US$ Million)

Table 81. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2018-2023)

Table 82. Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (K Units)

Table 83. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2024-2029)

Table 84. Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (US$ Million)

Table 85. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2024-2029)

Table 86. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Region (2018-2023) & (K Units)

Table 87. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2018-2023)

Table 88. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Region (2018-2023) & (US$ Million)

Table 89. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2018-2023)

Table 90. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Region (2024-2029) & (K Units)

Table 91. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2024-2029)

Table 92. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Region (2024-2029) & (US$ Million)

Table 93. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2024-2029)

Table 94. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (K Units)

Table 95. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2018-2023)

Table 96. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (US$ Million)

Table 97. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2018-2023)

Table 98. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (K Units)

Table 99. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2024-2029)

Table 100. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (US$ Million)

Table 101. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2024-2029)

Table 102. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (K Units)

Table 103. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2018-2023)

Table 104. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2018-2023) & (US$ Million)

Table 105. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2018-2023)

Table 106. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (K Units)

Table 107. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Country (2024-2029)

Table 108. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2024-2029) & (US$ Million)

Table 109. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Country (2024-2029)

Table 110. Ironwood Pharmaceuticals Company Information

Table 111. Ironwood Pharmaceuticals Introduction and Business Overview

Table 112. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 113. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product

Table 114. Ironwood Pharmaceuticals Recent Development

Table 115. Daiichi Sankyo Co Company Information

Table 116. Daiichi Sankyo Co Introduction and Business Overview

Table 117. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 118. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product

Table 119. Daiichi Sankyo Co Recent Development

Table 120. Pfizer Company Information

Table 121. Pfizer Introduction and Business Overview

Table 122. Pfizer Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 123. Pfizer Opioid Induced Constipation (OIC) Drug Product

Table 124. Pfizer Recent Development

Table 125. Progenics Pharmaceuticals Company Information

Table 126. Progenics Pharmaceuticals Introduction and Business Overview

Table 127. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 128. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product

Table 129. Progenics Pharmaceuticals Recent Development

Table 130. Shionogi & Company Information

Table 131. Shionogi & Introduction and Business Overview

Table 132. Shionogi & Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 133. Shionogi & Opioid Induced Constipation (OIC) Drug Product

Table 134. Shionogi & Recent Development

Table 135. Allergan Company Information

Table 136. Allergan Introduction and Business Overview

Table 137. Allergan Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 138. Allergan Opioid Induced Constipation (OIC) Drug Product

Table 139. Allergan Recent Development

Table 140. Nektar Therapeutics Company Information

Table 141. Nektar Therapeutics Introduction and Business Overview

Table 142. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 143. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product

Table 144. Nektar Therapeutics Recent Development

Table 145. Purdue Pharma Company Information

Table 146. Purdue Pharma Introduction and Business Overview

Table 147. Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 148. Purdue Pharma Opioid Induced Constipation (OIC) Drug Product

Table 149. Purdue Pharma Recent Development

Table 150. S.L.A. Pharma Company Information

Table 151. S.L.A. Pharma Introduction and Business Overview

Table 152. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 153. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product

Table 154. S.L.A. Pharma Recent Development

Table 155. Mundipharma International Limited Company Information

Table 156. Mundipharma International Limited Introduction and Business Overview

Table 157. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 158. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product

Table 159. Mundipharma International Limited Recent Development

Table 160. Ono Pharmaceutical Company Information

Table 161. Ono Pharmaceutical Introduction and Business Overview

Table 162. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 163. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product

Table 164. Ono Pharmaceutical Recent Development

Table 165. Takeda Pharmaceutical Company Limited Company Information

Table 166. Takeda Pharmaceutical Company Limited Introduction and Business Overview

Table 167. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 168. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product

Table 169. Takeda Pharmaceutical Company Limited Recent Development

Table 170. Theravance Biopharma Company Information

Table 171. Theravance Biopharma Introduction and Business Overview

Table 172. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 173. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product

Table 174. Theravance Biopharma Recent Development

Table 175. Bausch Health Company Information

Table 176. Bausch Health Introduction and Business Overview

Table 177. Bausch Health Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 178. Bausch Health Opioid Induced Constipation (OIC) Drug Product

Table 179. Bausch Health Recent Development

Table 180. Cosmo Pharmaceuticals SA Company Information

Table 181. Cosmo Pharmaceuticals SA Introduction and Business Overview

Table 182. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 183. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product

Table 184. Cosmo Pharmaceuticals SA Recent Development

Table 185. Daewoong Pharmaceutical Company Information

Table 186. Daewoong Pharmaceutical Introduction and Business Overview

Table 187. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 188. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product

Table 189. Daewoong Pharmaceutical Recent Development

Table 190. C.B. Fleet Company Company Information

Table 191. C.B. Fleet Company Introduction and Business Overview

Table 192. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 193. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product

Table 194. C.B. Fleet Company Recent Development

Table 195. Sucampo Pharmaceuticals Company Information

Table 196. Sucampo Pharmaceuticals Introduction and Business Overview

Table 197. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)

Table 198. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product

Table 199. Sucampo Pharmaceuticals Recent Development

Table 200. Key Raw Materials Lists

Table 201. Raw Materials Key Suppliers Lists

Table 202. Opioid Induced Constipation (OIC) Drug Market Trends

Table 203. Opioid Induced Constipation (OIC) Drug Market Drivers

Table 204. Opioid Induced Constipation (OIC) Drug Market Challenges

Table 205. Opioid Induced Constipation (OIC) Drug Market Restraints

Table 206. Opioid Induced Constipation (OIC) Drug Distributors List

Table 207. Opioid Induced Constipation (OIC) Drug Downstream Customers

Table 208. Research Programs/Design for This Report

Table 209. Key Data Information from Secondary Sources

Table 210. Key Data Information from Primary Sources

List of Figures

Figure 1. Opioid Induced Constipation (OIC) Drug Product Picture

Figure 2. Global Opioid Induced Constipation (OIC) Drug Market Size, 2018 VS 2022 VS 2029 (US$ Million)

Figure 3. Global Opioid Induced Constipation (OIC) Drug Market Size Status and Outlook (2018-2029) & (US$ Million)

Figure 4. Global Opioid Induced Constipation (OIC) Drug Sales Status and Outlook (2018-2029) & (K Units)

Figure 5. Product Picture of Lubiprostone

Figure 6. Global Lubiprostone Sales YoY Growth (2018-2029) & (K Units)

Figure 7. Product Picture of Methyl Naltrexone Bromide

Figure 8. Global Methyl Naltrexone Bromide Sales YoY Growth (2018-2029) & (K Units)

Figure 9. Product Picture of Naldemedine

Figure 10. Global Naldemedine Sales YoY Growth (2018-2029) & (K Units)

Figure 11. Product Picture of Alvimopan

Figure 12. Global Alvimopan Sales YoY Growth (2018-2029) & (K Units)

Figure 13. Product Picture of Other

Figure 14. Global Other Sales YoY Growth (2018-2029) & (K Units)

Figure 15. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2018-2029) & (US$ Million)

Figure 16. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Type in 2022 & 2029

Figure 17. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2022

Figure 18. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2022

Figure 19. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2022

Figure 20. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2022

Figure 21. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2022

Figure 22. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2022

Figure 23. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2022

Figure 24. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2022

Figure 25. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2022

Figure 26. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2022

Figure 27. The 5 and 10 Largest Manufacturers in the World: Market Share by Opioid Induced Constipation (OIC) Drug Sales in 2022

Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by Opioid Induced Constipation (OIC) Drug Revenue in 2022

Figure 29. Opioid Induced Constipation (OIC) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 30. Product Picture of Hospital Pharmacies

Figure 31. Global Hospital Pharmacies Sales YoY Growth (2018-2029) & (K Units)

Figure 32. Product Picture of Retail Pharmacies

Figure 33. Global Retail Pharmacies Sales YoY Growth (2018-2029) & (K Units)

Figure 34. Product Picture of Online Pharmacies

Figure 35. Global Online Pharmacies Sales YoY Growth (2018-2029) & (K Units)

Figure 36. Global Opioid Induced Constipation (OIC) Drug Sales by Distribution Channel (2018-2029) & (US$ Million)

Figure 37. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Distribution Channel in 2022 & 2029

Figure 38. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel in 2022

Figure 39. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel in 2022

Figure 40. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel in 2022

Figure 41. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel in 2022

Figure 42. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel in 2022

Figure 43. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel in 2022

Figure 44. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Distribution Channel in 2022

Figure 45. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel in 2022

Figure 46. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Distribution Channel in 2022

Figure 47. Key Raw Materials Price

Figure 48. Opioid Induced Constipation (OIC) Drug Manufacturing Cost Structure

Figure 49. Opioid Induced Constipation (OIC) Drug Industrial Chain Analysis

Figure 50. Channels of Distribution

Figure 51. Distributors Profiles

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions